Mania Radfar

Mania Radfar

Auto-generated profile, based on publicly available information

Mania Radfar

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Canadian Journal of Diabetes
Verified
Journal Article
Open access
SSSeyedeh Maryam Sadati
Seyedeh Maryam Sadati
MRMania Radfar
Mania Radfar
AHArmita Kakavand Hamidi
Armita Kakavand Hamidi
MAMohammad Abdollahi
Mohammad Abdollahi
MQMostafa Qorbani
Mostafa Qorbani
MAMahsa M. Amoli
Mahsa M. Amoli
Diabetic foot ulcer (DFU) is a common and major manifestation in patients with diabetes. Oxidative stress (OS) plays an important role in diabetic complications, such as DFU. Nitric oxide deficiency contributes to the impairment of diabetic wound healing. The aim of this study was to examine the association between the eNOS Glu298Asp polymorphism and DFU and oxidative stress in patients with type 2 diabetes mellitus in an Iranian population. In this case-control study, 123 patients with type 2 diabetes and DFU and 134 patients without DFU were recruited. The genotypes of eNOS Glu298Asp polymorphism in exon 7 were determined by the polymerase chain reaction-restriction fragment length polymorphism analysis. We measured the levels of thiobarbituric reactive substances and ferric-reducing ability of plasma as the potential markers of OS. There were significant differences in genotype frequencies of eNOS Glu298Asp polymorphism between case and control groups (GG+TG vs. TT; p=0.002; OR=0.22, 95% CI 0.83 to 0.62). Also, the frequency of the T allele in cases was less common than in controls (p=0.004). There was no significant difference in levels of OS parameters and various genotypes (p>0.05). These results imply that the T allele might be protective against DFU.

1 February 2018 in Pharmacological Reports
Verified
Journal Article
Closed access
AHArmita Kakavand Hamidi
Armita Kakavand Hamidi
MRMania Radfar
Mania Radfar
MAMahsa M. Amoli
Mahsa M. Amoli

17 May 2022 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
MOMohammad Bagher Oghazian
Mohammad Bagher Oghazian
NSNooshin Shirzad
Nooshin Shirzad
MAMahdi Ahadi
Mahdi Ahadi
SAShalaleh Eivazi Adli
Shalaleh Eivazi Adli
SMSamaneh Mollazadeh
Samaneh Mollazadeh
MRMania Radfar
Mania Radfar
Estrogen is involved in the pathogenesis of breast and gynecological cancers. Regular use of aspirin reduces estrogen levels. The present study aimed to evaluate the effect of aspirin on estrogen levels in postmenopausal women. This double-blind, placebo-controlled parallel-group trial was conducted on postmenopausal women referred to an outpatient clinic at a women’s hospital in Tehran. Volunteers were randomly assigned to receive aspirin 100 mg/day or placebo for 6 weeks. Estradiol, sex hormone-binding globulin (SHBG), and testosterone levels at baseline and at the end of the intervention were measured by ELISA. Data were analyzed using SPSS 20, Kolmogorov–Smirnov test, independent samples t-test, and Mann–Whitney U test. Twenty-seven and 28 participants were finally analyzed in the aspirin and placebo groups, respectively. There was no significant difference between the two groups in body mass index (BMI), age, or menopausal years. There was a statistically significant difference (p = 0.002) in the amount of change in estradiol levels of the intervention group (median=− 3.5 pg/ml) compared to the control group (median=1.5 pg/ml). In contrast, there were no significant differences between the two groups regarding testosterone and SHBG levels (p = 0.58, p = 0.32). Since low doses of aspirin may decrease estradiol levels, it could be considered a promising adjunctive therapeutic candidate in postmenopausal women to decrease BC incidence. However, further studies with larger sample sizes, measurements of estrogen levels and its related compounds in different time points accompanied by long-term follow-ups are needed to better elucidate the potential mechanisms by which nonsteroidal anti-inflammatory drugs (NSAIDs) negatively affect breast cancer. IRCT201012195397N1. Date of first registration: 03/01/2011.

1 October 2013 in European Urology Supplements
Verified
Journal Article
Closed access
SZS.A.M. Ziaee
S.A.M. Ziaee
MRM.H. Radfar
M.H. Radfar
ANA. Nouralizadeh
A. Nouralizadeh
AMA. Modir
A. Modir
RFR. Farjad
R. Farjad